Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Social Network Barriers to Extended-Release Naltrexone Within Rural Appalachia: Perspectives from Justice-Involved Clients and Clinicians.
Subst Use Misuse
January 2025
Center on Drug & Alcohol Research, University of Kentucky, Lexington, KY, US.
Background: Extended-release naltrexone (XR-NTX, Vivitrol) is an effective, but underutilized, evidence-based treatment for people with opioid use disorder (POUD) who are incarcerated. Networks of family, friends, and clinicians serve as social influencers of health behaviors, including XR-NTX initiation, and are especially salient in Appalachia.
Objectives: Using a triangulation of perspectives, this study examined concordance between the social network themes that emerged from qualitative interviews with clinicians and POUD social network findings.
Potential Cardiovascular Risks Associated with Naltrexone-Bupropion Treatment in Overweight Patients [Response to Letter].
Drug Des Devel Ther
January 2025
Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Low-dose naltrexone as a treatment for vulvodynia: A case series.
Case Rep Womens Health
March 2025
Division of Minimally Invasive Gynecology Surgery, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, 460 Waterstone Drive, Hillsborough, NC 27278, USA.
Vulvodynia is a chronic vulvar pain condition that can be challenging to treat and often requires multi-modal interventions for symptom management. Low-dose naltrexone (LDN) is a reversible competitive antagonist at opioid receptors and may have utility in treating chronic pain conditions. In a specialty gynecology clinic at an academic medical center, patients with poorly controlled vulvodynia who had failed standard treatments were offered LDN as an adjunct pain treatment.
View Article and Find Full Text PDFFibromyalgia: do I tackle you with pharmacological treatments?
Pain Rep
February 2025
Pain Department, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris Cité University, INSERM U987, Paris, France.
Pharmacological approaches are frequently proposed in fibromyalgia, based on different rationale. Some treatments are proposed to alleviate symptoms, mainly pain, fatigue, and sleep disorder. Other treatments are proposed according to pathophysiological mechanisms, especially central sensitization and abnormal pain modulation.
View Article and Find Full Text PDFOGFr overexpression exerts anti-hepatocellular carcinoma effects by activating P16 and P21 to inhibit proliferation and migration of HepG2 cells.
Folia Histochem Cytobiol
January 2025
Department of Colorectal Surgery, Hangzhou Red Cross Hospital, Hangzhou, China.
Introduction: Hepatocellular carcinoma (HCC) is the sixth most common type of cancer and the second leading cause of cancer death worldwide [19]. Opioid growth factor (OGF) has been shown to exhibit antitumour potential, binding to OGF receptor (OGFr). Naltrexone (NTX), an OGFr antagonist, is considered as a potential anti-cancer agent.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!